Risk for Rapid Progression Explored in Patients With CKD Stage G3
By Elana Gotkine HealthDay Reporter
WEDNESDAY, March 13, 2024 -- Individuals with incident chronic kidney disease (CKD) stage G3 have a 14.6 percent three-year risk for rapid progression, according to a study recently published in Nephrology Dialysis Transplantation.
Anne H.S. Vestergaard, M.D., Ph.D., from Aarhus University in Denmark, and colleagues conducted a nationwide, population-based cohort study to examine the risk for rapid progression, kidney failure, hospitalization, and death among adults with incident CKD stage G3 in 2017 to 2020. Risk markers were examined by constructing a heat map showing the risk for rapid progression based on predefined markers.
The researchers found that the three-year risk for rapid progression was 14.6 percent among 133,443 individuals with incident CKD stage G3. The three-year risks were 0.3, 53.3, and 18.1 percent for kidney failure, hospitalization, and death, respectively. The three-year risk for rapid progression in the heat map varied from 7 percent in women without albuminuria, hypertension/cardiovascular disease, or diabetes to 46 to 47 percent in men and women with severe albuminuria, diabetes, and hypertension/cardiovascular disease.
"The present population-based study highlights the potential for using readily available markers in routine clinical care to identify individuals at particularly high risk of rapid progression of CKD who may benefit from regular monitoring and prophylactic interventions to slow further decline in kidney function and associated adverse events," the authors write.
Several authors disclosed ties to AstraZeneca, which funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
Cardiovascular, Kidney, and Metabolic Syndrome Highly Prevalent in the U.S.
FRIDAY, May 10, 2024 -- Cardiovascular, kidney, and metabolic (CKM) syndrome is highly prevalent in the United States, with more than 90 percent of adults meeting the criteria for...
SGLT2 Inhibitors Improve Outcomes in Patients With Diabetes Plus Kidney Disease
THURSDAY, May 2, 2024 -- Use of sodium–glucose cotransporter-2 inhibitors (SGLT2is) is associated with a substantially lower risk for dialysis and cardiovascular disease in...
Leukocyte Glucose Index, Arteriovenous Fistula Failure Linked in ESKD
MONDAY, April 22, 2024 -- For patients with end-stage kidney disease (ESKD), a high preoperative leukocyte glucose index (LGI) is associated with arteriovenous fistula (AVF)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.